STOCK TITAN
  1. Home
  2. Sec-filings
  3. MANE
  4. [Form 4] Veradermics, Inc Insider Trading Activity

Veradermics (MANE) CTO unloads tens of thousands of shares in preset trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Veradermics, Inc (MANE) reported that its Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares of Common Stock at an exercise price of $12.19 per share and on the same date sold an aggregate of 43,500 Common shares in multiple open-market transactions at weighted average prices ranging from about $106.71 to $111.28 per share. The option was fully vested and exercisable, and the transactions were made pursuant to a Rule 10b5-1 trading plan.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Durso Timothy August
Role Chief Technical Officer
Sold 43,500 shs ($4.69M)
Approx. gross sale proceeds $4.69M
Approx. exercise cost $42K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F5 3,452 $0.00 $0.00
Exercise Common Stock 3,452 $12.19 $42K
Sale Common Stock F1 7,918 $106.71 $845K
Sale Common Stock F2 16,306 $107.52 $1.75M
Sale Common Stock F3 16,767 $108.38 $1.82M
Sale Common Stock F4 2,348 $109.34 $257K
Sale Common Stock 161 $111.28 $18K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 78,142 shares (Direct)
Footnotes (5)
  1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.25 to $106.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $107.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.00 to $109.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. F5. This option is fully vested and exercisable as of the date hereof.
Options Exercised 3,452 shares Stock Option (Right to Buy) exercised into Common Stock on 2026-08-17
Option Exercise Price $12.19 per share Exercise price for 3,452-share stock option
Total Shares Sold 43,500 shares Aggregate Common Stock sold on 2026-08-17
Sale Price Tranche 1 $106.71 per share Weighted average price for 7,918-share sale, range $106.25–$106.99
Sale Price Tranche 2 $107.52 per share Weighted average price for 16,306-share sale, range $107.00–$107.99
Sale Price Tranche 3 $108.38 per share Weighted average price for 16,767-share sale, range $108.00–$108.99
Sale Price Tranche 4 $109.34 per share Weighted average price for 2,348-share sale, range $109.00–$109.96
Sale Price Tranche 5 $111.28 per share Price for 161-share sale of Common Stock
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 trading plan regulatory
"transactions were made pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

What insider transactions did MANE’s CTO report on this Form 4?
The CTO of Veradermics, Inc (MANE) reported exercising 3,452 stock options at $12.19 per share and selling 43,500 Common shares on August 17, 2026. The sales occurred in multiple open-market trades at various weighted average prices above $106 per share.

How many Veradermics (MANE) shares did the CTO sell and at what prices?
The CTO sold 43,500 shares of Common Stock of Veradermics (MANE) on August 17, 2026. The shares were sold in several tranches at weighted average prices of $106.71, $107.52, $108.38, $109.34, and $111.28 per share, each with specified intraday price ranges.

What stock option exercise did the Veradermics (MANE) CTO report?
The CTO exercised a Stock Option (Right to Buy) covering 3,452 shares of Veradermics (MANE) Common Stock at an exercise price of $12.19 per share. The option was fully vested and exercisable as of the transaction date, and was then fully exercised.

Were the MANE insider sales made under a Rule 10b5-1 trading plan?
Yes. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan. Such plans pre-arrange trade timing and amounts, which can reduce the informational value of transaction timing about the insider’s current view of Veradermics (MANE).

What was the overall direction of the MANE insider’s reported trades?
Overall activity on this Form 4 reflects a net sale of 43,500 shares of Veradermics (MANE) Common Stock. Although 3,452 options were exercised into shares, the insider’s reported open-market dispositions far exceeded the acquired amount, resulting in net selling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Durso Timothy August
(Last)(First)(Middle)
C/O VERADERMICS, INCORPORATED
470 JAMES ST.
(Street)
NEW HAVEN CONNECTICUT 06513
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/17/2026M3,452A$12.19121,642D
Common Stock08/17/2026S7,918D$106.71(1)113,724D
Common Stock08/17/2026S16,306D$107.52(2)97,418D
Common Stock08/17/2026S16,767D$108.38(3)80,651D
Common Stock08/17/2026S2,348D$109.34(4)78,303D
Common Stock08/17/2026S161D$111.2878,142D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$12.1908/17/2026M3,452 (5)12/12/2026Common Stock3,452$00D
Explanation of Responses:
1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.25 to $106.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $107.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.00 to $109.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5. This option is fully vested and exercisable as of the date hereof.
Remarks:
/s/ Michael Greco, Attorney-in-Fact08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR